# Amicus Therapeutics clinical trials: 42 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 42 trials with Amicus Therapeutics as lead sponsor, 5 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Amicus Therapeutics: 42 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/amicus-therapeutics

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 42
- Recruiting or not yet: 5
- Read on: November 19, 2026

## Trials

The 25 newest of 42, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| April 2, 2025 | NCT06906367 | A Study of Patients With Fabry Disease (US Specific) | Amicus Therapeutics | Observational | Recruiting | Fabry Disease | 450 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06906367) |
| April 1, 2025 | NCT06904261 | A Study of Migalastat in Pediatric Subjects (2 to \<12 Yrs) With Fabry Disease and Amenable GLA Variants | Amicus Therapeutics | Phase 3 | Recruiting | Fabry Disease | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06904261) |
| November 7, 2023 | NCT06121011 | A Global Prospective Observational Registry of Patients With Pompe Disease | Amicus Therapeutics | Observational | Recruiting | Pompe Disease | 500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06121011) |
| March 22, 2021 | NCT04808505 | A Study to Evaluate the Safety, Efficacy, PK, PD and Immunogenicity of Cipaglucosidase Alfa/Miglustat in IOPD Subjects Aged 0 to \<18 | Amicus Therapeutics | Phase 3 | Recruiting | Glycogen Storage Disease Type II Infantile Onset | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04808505) |
| March 18, 2021 | NCT04804566 | Understanding Fabry Disease Therapy Choices Through the Eyes of the Patients | Amicus Therapeutics | Observational | Completed | Fabry Disease | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04804566) |
| March 31, 2020 | NCT04327973 | Expanded Access for ATB200/AT2221 for the Treatment of IOPD | Amicus Therapeutics | Not applicable | Available | Pompe Disease Infantile-Onset | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04327973) |
| February 24, 2020 | NCT04281537 | A Study to Describe the Experience of Both Patients and Their Clinicians in the Treatment of Fabry Disease With Enzyme Replacement Therapy. | Amicus Therapeutics | Observational | Completed | Fabry Disease | 82 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04281537) |
| February 5, 2020 | NCT04252066 | A Global Prospective Observational Study of Women With Fabry Disease and Their Infants During Pregnancy and Breastfeeding | Amicus Therapeutics | Observational | Recruiting | Fabry Disease | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04252066) |
| October 24, 2019 | NCT04138277 | A Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With Late-Onset Pompe Disease (LOPD) | Amicus Therapeutics | Phase 3 | Completed | Pompe Disease (Late-onset) | 119 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04138277) |
| August 8, 2019 | NCT04049760 | Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged \>12 Years) With Fabry Disease | Amicus Therapeutics | Phase 3 | Completed | Fabry Disease | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04049760) |
| July 15, 2019 | NCT04020055 | A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease | Amicus Therapeutics | Phase 3 | Active not recruiting | Fabry Disease | 14 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04020055) |
| April 11, 2019 | NCT03911505 | ZIP Study-OL Study of Safety, PK, Efficacy, PD, Immunogenicity of ATB200/AT2221 in Pediatrics Aged 0 to \< 18 y.o. w/LOPD | Amicus Therapeutics | Phase 3 | Active not recruiting | Pompe Disease (Late-onset) | 21 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03911505) |
| March 7, 2019 | NCT03865836 | Expanded Access for ATB200/AT2221 for the Treatment of Pompe Disease | Amicus Therapeutics | Not applicable | Available | Pompe Disease | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03865836) |
| November 2, 2018 | NCT03729362 | A Study Comparing ATB200/AT2221 With Alglucosidase Alfa/Placebo in Adult Subjects With Late-onset Pompe Disease | Amicus Therapeutics | Phase 3 | Completed | Pompe Disease (Late-onset) | 125 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03729362) |
| April 17, 2018 | NCT03500094 | Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged 12 to \<18 Years) | Amicus Therapeutics | Phase 3 | Completed | Fabry Disease | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03500094) |
| November 20, 2017 | NCT03347253 | STRIDE Study - A Study in Subjects With LOPD Who Are Currently Being Treated With ERT | Amicus Therapeutics | Observational | Terminated | Late-onset Pompe Disease | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03347253) |
| May 18, 2017 | NCT03158662 | Survey to Identify Burdens and Unmet Needs of Patients With Epidermolysis Bullosa | Amicus Therapeutics | Observational | Completed | Epidermolysis Bullosa | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03158662) |
| February 5, 2016 | NCT02675465 | First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2221 | Amicus Therapeutics | Phase 1/2 | Completed | Pompe Disease | 29 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02675465) |
| July 21, 2014 | NCT02194985 | Open-Label Extension Study of the Long-Term Effects of Migalastat HCL in Patients With Fabry Disease | Amicus Therapeutics | Phase 3 | Completed | Fabry Disease | 84 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02194985) |
| March 10, 2014 | NCT02082327 | A Phase 1 Study To Evaluate the Safety of Migalastat Hydrochloride Given Intravenously to Healthy Volunteers | Amicus Therapeutics | Phase 1 | Completed | Fabry Disease | 31 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02082327) |
| May 15, 2013 | NCT01853852 | A Phase I, Randomized, Single-Blind, Four-Period Cross-Over, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety and... | Amicus Therapeutics | Phase 1 | Completed | Fabry Disease | 14 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01853852) |
| November 21, 2012 | NCT01730482 | A Study to Assess the Absorption, Metabolism and Excretion of Migalastat Hydrochloride (AT1001-014) | Amicus Therapeutics | Phase 1 | Completed | Fabry Disease | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01730482) |
| November 21, 2012 | NCT01730469 | Safety and Pharmacokinetics of AT1001 (Migalastat HCl) in Healthy Subjects and Subjects With Impaired Renal Function | Amicus Therapeutics | Phase 1 | Completed | Fabry Disease | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01730469) |
| December 12, 2011 | NCT01489995 | Migalastat Food Effect Study | Amicus Therapeutics | Phase 1 | Completed | Fabry Disease | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01489995) |
| November 22, 2011 | NCT01476163 | Physician Initiated Expanded Access Request for Migalastat in Individual Patients With Fabry Disease | Amicus Therapeutics | Not applicable | Available | Fabry Disease | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01476163) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 6 |
| Phase 1/2 | 1 |
| Phase 2 | 11 |
| Phase 3 | 12 |
| Not applicable | 3 |
| Observational | 9 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 27 |
| Terminated | 5 |
| Recruiting | 5 |
| Available | 3 |
| Active not recruiting | 2 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Fabry Disease | 24 |
| Glycogen Storage Disease Type II | 9 |
| Gaucher Disease | 5 |
| Lysosomal Storage Diseases | 4 |
| Epidermolysis Bullosa | 1 |
| Hypohidrosis | 1 |
| Proteinuria | 1 |
| Angiokeratoma | 1 |
| Metabolism, Inborn Errors | 1 |
| Metabolic Diseases | 1 |
| Sphingolipidoses | 1 |
| Genetic Diseases, Inborn | 1 |
| Kidney Diseases | 1 |
| Renal Insufficiency | 1 |
| Kidney Failure, Chronic | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Hazardous waste disposal companies in the United States](https://specstream.ai/data/businesses/hazardous-waste-disposal-companies/united-states)
- [Ophthalmology practices in the United States](https://specstream.ai/data/businesses/ophthalmology-practices/united-states)
- [Sri Lankan restaurants in the United States](https://specstream.ai/data/businesses/sri-lankan-restaurants/united-states)
- [B2B direct mail advertising companies in the United States](https://specstream.ai/data/businesses/b2b-direct-mail-advertising-companies/united-states)
- [Diagnostic imaging centers in the United States](https://specstream.ai/data/businesses/diagnostic-imaging-centers/united-states)
- [Hydro jetting companies in the United States](https://specstream.ai/data/businesses/hydro-jetting-companies/united-states)
